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The Treatment of Vasomotor Rhinitis With
Intranasal Corticosteroids
Eli O. Meltzer, MD
Objective: Intranasal steroids (INS) are firmly established as the
therapy for choice for allergic rhinitis, but their role in vasomotor
rhinitis (VMR) is not fully characterized. This review examines the
potential mechanisms of action and reported efficacy of INS in
patients with VMR.
Results: INS, through intracellular activation of the glucocorticoid
receptor, down-regulate the recruitment and activation of inflamma-
tory cells (T-lymphocytes, eosinophils, mast cells, basophils, neu-
trophils, macrophages), increase degradation of neuropeptides, and
reduce epithelial cell activity, vascular permeability, and chemokine
secretion. It is likely that more than vasoconstriction is responsible
for the clinical effects of INS.
Eight INS can be prescribed for rhinitis in the US; only 4 have
been studied for VMR. Seventy-four percent of patients treated with
beclomethasone dipropionate considered themselves symptom-free
or greatly improved versus 31% with placebo. Budesonide signifi-
cantly reduced rhinitis symptoms and methacholine-induced nasal
secretions compared with placebo. Fluticasone propionate compared
with placebo provided significantly greater relief from nasal obstruc-
tion; computed tomographic scans showed significant reductions in
the mucosal area of the lower turbinates. Mometasone furoate
produced numerically better rhinitis symptom scores and, when
discontinued, lower relapse rates than placebo.
Conclusion: Data supports INS as beneficial pharmacotherapy for
VMR.
Key Words: nonallergic rhinitis, vasomotor rhinitis, intranasal
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fluticasone propionate, mometasone furoate
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INTRODUCTION
Vasomotor rhinitis (VMR, also referred to as idiopathicrhinitis) is diagnosed in a heterogeneous group of patients
with chronic nasal symptoms that are not immunologic or
infectious in origin and usually not associated with nasal
eosinophilia. Although the term vasomotor implies increased
neural efferent traffic to the blood vessels supplying the
nasal mucosa, this has never been proven.1 However, it is
suggested that neurogenic reflex mechanisms initiated by
environmental factors may be involved. There could be an
imbalance of the sympathetic and parasympathetic nervous
systems, with parasympathetic hyperactivity and sympa-
thetic hypoactivity resulting in rhinorrhea and nasal con-
gestion. Indirect evidence also postulates that C-fibers may
play a role in the pathophysiology of VMR.2 According to
this second theory, in nonallergic, noninfectious perennial
rhinitis an overactive nonadrenergic, noncholinergic sys-
tem causes neurogenic inflammation, resulting in increased
neuropeptides.3 The recently updated rhinitis parameters
developed by the Joint Task Force on Practice Parameters,
representing the American Academy of Allergy, Asthma
and Immunology, the American College of Allergy, Asthma and
Immunology, and the Joint Council of Allergy, Asthma and
Immunology state, “intranasal corticosteroids are effective in the
treatment of vasomotor rhinitis.”1
INTRANASAL CORTICOSTEROIDS
Intranasal corticosteroids (INSs) are effective therapeu-
tic agents. In recent years, increased understanding of corti-
costeroid and glucocorticoid receptor pharmacology has en-
abled the development of molecules designed specifically to
achieve potent, localized activity with minimal risk of sys-
temic exposure.
Systemic corticosteroids, which were developed in the
1950s, are effective in treating various rhinopathies; but the
high risk of serious toxicity with long-term administration has
hindered their usefulness.4 Initial attempts to deliver com-
pounds such as hydrocortisone and dexamethasone directly
into the airways were only partially successful.5 The first
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successful use of beclomethasone dipropionate (BDP) as a
pressurized aerosol with no apparent evidence of systemic
toxicity was published in 1972.5 In the years since, cortico-
steroid molecules have been refined to create more potent
agents with lower bioavailability and enhanced safety pro-
files. Currently, 8 INS compounds are approved for the
management of allergic rhinitis (AR) in the United States:
BDP, budesonide, ciclesonide, flunisolide, fluticasone fu-
FIGURE 1. Chemical structures of intranasal steroids.6
TABLE 1. Available Intranasal Corticosteroids
Generic (Proprietary) Name Recommended Dosage
Beclomethasone dipropionate Adults and children 12 years of age: 1 or 2 sprays (42 to 84 g) per nostril BID (total dose 168 to 336 g/d)
(Beconase AQ) Children 6–12 years: 1 spray (42 g) per nostril BID for total of 168 g/d up to 2 sprays per nostril BID for
total of 336 g/d
Budesonide (Rhinocort Aqua)* Adults and children 6 years of age: 1 spray (32 g/spray) per nostril QD up to a maximum of 256 g/d
(12 years of age) or 128 g/d (6 to 12 years of age)
Ciclesonide (Omnaris) Adults and children 12 years of age: 2 sprays (50 g/spray) per nostril QD
Flunisolide (Nasarel) Adults: 2 sprays (58 g) per nostril BID, not to exceed 8 sprays per nostril per day (464 g)
Children 6–14 years of age: 1 spray (29 g) per nostril TID or 2 sprays (58 g) per nostril BID, not to exceed
4 sprays per nostril per day (232 g)
Fluticasone furoate (Veramyst) Adults and children 12 years of age: 2 sprays (55 g) per nostril QD
Children 2–11 years of age: 1 spray (27.5 g) per nostril QD up to 2 sprays (55 g) per nostril QD
Fluticasone propionate (Flonase) Adults: 2 sprays (100 g) per nostril QD or 1 spray (50 g) BID
Adolescents and children 4 years of age: 1 spray (50 g) per nostril per day up to, but not in excess of, 2
sprays (100 g) per nostril per day
Mometasone furoate (Nasonex) Adults and children 12 years of age: 2 sprays (100 g) per nostril QD
Children 2–11 years of age: 1 spray (50 g) per nostril QD
Triamcinolone acetonide Adults and children 12 years of age: 2 sprays (110 g) per nostril QD
(Nasacort AQ) Children 6–12 years of age: 1 spray (55 g) per nostril or 110 g QD, up to 2 sprays (110 g each) per
nostril or 220 g QD
*Available in 2 strengths: 32 and 64 g per spray.
WAO Journal • August 2009 Intranasal Corticosteroids for Vasomotor Rhinitis
© 2009 World Allergy Organization 167
roate, fluticasone propionate (FP), mometasone furoate, and
triamcinolone acetonide (Table 1).6
Corticosteroid molecules are derived from the parent
molecule, cortisol.7 The carbon framework of each cortico-
steroid is made up of three 6-carbon rings as shown in Figure
1 (rings A, B, and C) and one 5-carbon ring (ring D).6 All
anti-inflammatory corticosteroids have features in common
with cortisol and with each other: a ketone oxygen at position
3; an unsaturated bond between carbons 4 and 5; a hydroxyl
group at position 11; and a ketone oxygen group on carbon
20. The variations occurring off ring D at positions 16, 17,
and 21 are the greatest differentiating factors between the
individual molecules. Structure-activity relationship studies
of this region led to the identification of chemical groups that
enhance topical activity and reduce systemic adverse events.4
For example, the furoate group of mometasone furoate was
found to enhance molecular affinity for the glucocorticoid
receptor binding site.
Other modifications have improved the activity of corti-
costeroid compounds. The 21-chloro 17 (2 furoate) group on
the mometasone furoate structure improves anti-inflammatory
activity, whereas the chloride at position 21 provides the addi-
tional benefit of inferring resistance to degradation by esterases.4
Halogen substitutions at positions 6 and 9 are thought to increase
potency, as are side-chain substitutions at position 17.8
The pharmacotherapeutic objective of INS is to down-
regulate the recruitment and influx of inflammatory cells and
inhibit the secretion of pro-inflammatory mediators during
the inflammatory response.9 This process is evidenced in AR
FIGURE 2. Relative glucocorticoid receptor affinity of intranasal corticosteroids.6
TABLE 2. Effects of Corticosteroids on Inflammatory Cells
Cells Affected Corticosteroid Effect







Eosinophils Reduction of circulating cell number, apoptosis
Reduction of epithelial and mucosal cell counts
Reduction of cell influx in late-phase response
Inhibition of IL-4 and IL-5-mediated cell
survival
Mast cells/basophils Reduction of circulating cell counts
Reduction of cell influx in late-phase response
Reduction of mast cell-derived mediators after
challenge
Reduction of histamine content and release
Neutrophils Reduction of cell influx after challenge
Macrophages/monocytes Reduction of circulating cell counts
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by reduced levels of histamine, leukotrienes, and mast cells
recovered in the nasal fluid and mucosa of patients treated
with INSs.9–12
MECHANISMS OF ACTION OF INTRANASAL
CORTICOSTEROIDS
T-lymphocytes
Corticosteroid therapy provides a modest reduction in
the number of lymphocytes because of induction of pro-
grammed cell death or apoptosis.13 Topical administration
has been shown to inhibit T-lymphocyte activation, prevent
increases in interlukin-4 (IL-4), IL-5, and local IgE and
inhibit eosinophil recruitment and activation,14,15 IL-2 pro-
duction,16 and IL-2 generation.17
Eosinophils
Corticosteroids have well recognized effects on the
eosinophil component of the inflammatory process by
direct induction of eosinophil apoptosis18 and inhibition of
eosinophil recruitment and migration into the nasal air-
ways. Cytokine production in the airways may trigger this
cellular infiltration, and inhibition of cytokine production
is, therefore, one of the most important effects of cortico-
steroid therapy.19 Corticosteroids are effective and potent
inhibitors of cytokines such as tumor necrosis factor alpha
and IL-1, which induce secretion of the nonspecific endo-
thelial activators.20 They also inhibit the release of IL-4
and IL-13, thereby preventing expression of specific en-
dothelial cell adhesion molecules, which can bind ba-
sophils, eosinophils, monocytes, and lymphocytes.14 Cor-
ticosteroid treatment has been shown to inhibit the expression of
the chemokine RANTES in airway epithelial cells.21 Further-
more, corticosteroids inhibit the production of IL-3, IL-5, and
granulocyte-macrophage colony-stimulating factor (GM-CSF)22
and reduce eosinophil survival time.23
Thus, corticosteroids have multiple effects on eosino-
phils; they reduce the number of eosinophils in the circula-
tion, prevent recruitment of eosinophils to local tissue sites,24
reduce survival of eosinophils, and prevent production of
cytokines that are responsible for, or involved in, all of these
processes. Indeed, corticosteroids inhibit the production of
many cytokines that may explain much of their anti-inflam-
matory activity.
Mast Cells and Basophils
Topical corticosteroids can reduce inflammation by
affecting the infiltration of mast cells and basophils. Treat-
ment can decrease the number of mast cells in the nasal
mucosa.25,26 Corticosteroid treatment has also been shown
to markedly reduce the number of basophils in nasal
secretions.27 An associated reduction in the release of mast
cell mediators has been demonstrated after corticosteroid
treatment and interference with arachidonic acid metabo-
lism and a subsequent decrease in mediator production.28,29
Neutrophils
Corticosteroids are able to inhibit the accumulation of
neutrophils,30 possibly because of preventing neutrophil ad-
herence to vascular endothelium by suppressing the release of
endothelial-activating cytokines, for example, IL-1, IL-4, and
tumor necrosis factor alpha, and preventing the release of
factors that influence migration through the endothelial bar-
rier, for example, IL-8, tumor necrosis factor alpha, platelet
activating factor (PAF), and LTB4.31
Monocytes and Macrophages
Corticosteroids reduce the number of tissue macro-
phages and inhibit their release of IL-1, interferon gamma,
tumor necrosis factor alpha and GM-CSF (Table 2).19,32
Epithelial Cells
Human epithelial cells metabolize arachidonic acid.
Arachidonic acid metabolites, such as leukotrienes, prosta-
glandins, thromboxane, and PAF, have several activities,
TABLE 3. Potency of Topical Corticosteroids Based on











TABLE 4. Results During Treatment Periods With
Beclomethasone and Placebo
Sneezing Day 1 n.s.
Week 1 P  0.05
Week 2 P  0.01
Week 3 P  0.01
Week 4 P  0.01
Nasal catarrh Day 1 n.s.
Week 1 n.s.
Week 2 P  0.01
Week 3 P  0.01
Week 4 P  0.01
Itching Day 1 n.s.
Week 1 n.s.
Week 2 n.s.
Week 3 P  0.05
Week 4 P  0.05




Week 4 P  0.01
Total score Day 1 n.s.
Week 1 n.s.
Week 2 P  0.01
Week 3 P  0.01
Week 4 P  0.01
P-values favor treatment with beclomethasone.
n.s., not significant.
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including regulation of vascular tone and vascular permeabil-
ity, stimulation of mucus secretion, chemotaxis, and regula-
tion of cell proliferation. The cytokines produced by epithe-
lial cells can also mediate recruitment, activation, and
survival of inflammatory cells in the airway.33
Corticosteroids interfere with the inflammatory re-
sponse by blocking the production of arachidonic acid me-
tabolites in many cells. This is accomplished by inducing the
production of the anti-inflammatory protein, lipocortin, which
inhibits phospholipase A2, a central enzyme in the arachi-
donic acid cascade, thereby preventing the generation of
cyclo-oxygenase and lipoxygenase products.33
Blood Vessels
Topical corticosteroids reduce blood flow and inhibit
vascular permeability. The mechanisms for these actions
include a reduction in the cyclo-oxygenase metabolites
that maintain vascular beds, inhibition of phospholipase
A2, and the subsequent formation of leukotrienes and
PAF,34 inhibition of the release of endothelial-derived
relaxing factor, production of vasocortin (which reduces
permeability), and enhancement of vasospasm by alpha
adrenergic stimulation.35,36
Nerve Cells
Steroids have been reported to up-regulate neutral en-
dopeptidase that degrades neuropeptides37 and inhibits neu-
rogenic plasma extravasation.38
THE GLUCOCORTICOID RECEPTOR
Corticosteroid activity is mediated by intracellular
activation of the glucocorticoid receptor (GR).39,40 In its
inactive state, the GR exists as a cytosolic protein bound to
2 heat shock protein 90 chaperonin molecules. Binding to
the corticosteroid ligand results in a conformational change that
allows dissociation of the GR from the protein complex, and a
quick translocation into the cell nucleus. The ligand-bound GR
can modulate gene expression in the nucleus by binding to
glucocorticoid response elements in promoter regions of respon-
sive genes. The GR binds to the glucocorticoid response ele-
ments as a homodimer and acts as a transcription factor. It
has also become evident that the GR can regulate gene
expression unfacilitated by glucocorticoid response ele-
ments through direct interaction with transcription factors
such as nuclear factor NF-kappa B and activating pro-
tein.39,41,42 The inhibition of these 2 factors leads to down-
regulation of the production of cytokines and other inflam-
matory molecules and is thought to be among the primary
FIGURE 3. Efficacy of BDP aerosol for VMR. Symptom scores in each second week of every 2-week period of crossover trial
and the pretrial week (mean  SEM).52
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Glucocorticoid potency can be measured in various
ways, but is thought to be closely related to GR binding
affinity.6 Figure 2 illustrates the relative GR binding affinities
for most intranasal compounds. Relative receptor affinity
studies are highly dependent on assay methodology and prone
to error.43 Although specific values vary between studies,
most have shown a similar order of potency. An earlier study
of INSs that used competition assay methodology reported a
similar rank order of relative binding potency: mometasone
furoate  FP  budesonide  triamcinolone acetonide 
dexamethasone.40
Corticosteroid potency also has been evaluated using
the McKenzie assay, which compares the relative cutaneous
vasoconstrictor and skin blanching responses of individual
compounds.44 Using this methodology, the rank order of
potency was: FP  mometasone furoate  budesonide 
flunisolide  triamcinolone acetonide (Table 3).19,45 This
vasoconstriction phenomenon, which occurs in all subjects,
has been suggested as part of the explanation of the glucocor-
ticoid effect on the nasal mucosa. In a randomized double-
blind cross-over study, using the 133Xe wash-out method as
a measure of nasal mucosal blood flow, the effect of
topically administered budesonide was compared with pla-
cebo. No difference between the groups was found to
occur. It seems likely that a more complex activity than
vasoconstriction is responsible for the clinical effect of INS.46
Results of studies using another marker of corticoste-
roid potency, transactivation potency, correlate with receptor
FIGURE 4. Efficacy of budesonide for VMR. Symptom scores (mean  SEM) in budesonide versus placebo for each 2-week
crossover period.54




Run-in 49  4 49  5
Placebo 45  4 45  4
Budesonide 50 g 42  4 41  4
Budesonide 200 g 40  3 39  3
Budesonide 800 g 41  4 40  3
Significances from ANOVA
Run-in vs placebo and budesonide P  0.05 P  0.05
Placebo vs budesonide n.s. n.s.
Dosages within budesonide n.s. n.s.
n.s., not significant.
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binding affinity results. One study found mometasone furoate
the most potent GR ligand, requiring the lowest concentration
to affect 50% of the maximum level of transcription activa-
tion of a glucocorticoid response element reporter gene in
cells.40 Overall rank of potency using this methodology was:
mometasone furoate  FP  triamcinolone acetonide 
budesonide  dexamethasone.
There is no evidence of a linear association between
glucocorticoid potency and clinical response, nor is there a
known “plateau” beyond which greater potency does not
add additional benefit. Likewise, it is not evident that the
compound with the highest receptor affinity will have
superior clinical efficacy. Although increased potency at
intranasal sites would seem desirable, the possibility of
greater potency at other sites could theoretically increase
the risk of systemic adverse effects, because GRs are
similar throughout the body.
CLINICAL IMPLICATIONS
Onset of Action
It was traditionally accepted that INSs should be used
for days or weeks to achieve significant benefits, and because
these agents were used primarily to control chronic symp-
toms, few studies focused on onset of action.47 Symptom
improvement has been noted within 1 to 2 days after admin-
istration of most newer agents.47 It is not uncommon for
patients to use intranasal medications intermittently on an
“as-needed” basis,47 and such use may be justified given the
potential for a more rapid onset of action than was previously
ascribed to these medications.
Clinical Efficacy
The design of topically active INS formulations has
provided a much better therapeutic ratio than oral corticoste-
roids.36 The pharmacodynamic and pharmacokinetic proper-
ties of these agents play an important role in facilitating local
anti-inflammatory activity with a low rate of side effects.
However, it remains to be seen whether the often subtle
pharmacodynamic and pharmacokinetic differences between
the compounds distinguish them in a clinical setting.
FIGURE 5. Efficacy of budesonide aerosol 200 g twice daily, on symptoms of VMR in a long-term (1 year) open uncon-
trolled trial. Mean nasal symptom scores by month.55










Placebo 0.56 0.33 0.18 (P  0.05)
Budesonide
50 g
0.38 0.31 0.42 (P  0.01) 0.12 n.s.
Budesonide
200 g
0.31 0.35 0.42 (P  0.001) 0.09 (P  0.05)
Budesonide
800 g
0.29 0.20 0.37 (P  0.01) 0.06 (P  0.05)
n.s., not significant.
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Based on currently available data, there is no clear
evidence that any INS is superior to any other for AR
symptom relief47,48 despite the pharmacologic differences
between many of them. It is possible that the degree of
anti-inflammatory activity required for AR symptom relief is
low enough that relief is easily achieved by agents of varying
potencies, or that GR saturation or near saturation occurs with
all of the preparations.47,49 These considerations have not
been well studied in the treatment of VMR.
INTRANASAL CORTICOSTEROID THERAPY FOR
VASOMOTOR RHINITIS
INSs are one of the classes of agents that have received
US Federal Drug Administration approval for use in nonal-
lergic rhinitis. Specific formulations that are approved are
BDP aqueous, budesonide aerosol, and FP aqueous. It is
assumed that the anti-inflammatory activities of the INSs
account for their beneficial effect in VMR.50
BDP
BDP was first reported to be effective for VMR in
1976.50 In Sweden 39 male and female patients aged 19–66
years (average, 39 years) with perennial nasal obstruction,
drip, itching, and sneezing were studied in a randomized,
double-blind, placebo-controlled, 4-week treatment period
crossover designed trial. Intracutaneous specific aeroallergen
testing for these subjects was negative, but serum total IgE
ranged from 100 ng/ml (N  21), 101–200 ng/ml (N  8),
200–400 ng/ml (N  6), 401–900 ng/ml (N  3), to 1200
ng/ml (N  1). Nasal secretion eosinophilic cells were
estimated to be10%. The dosage was one aerosol-delivered
puff into each nostril 3 times a day (300 g of BDP per day
during the active period).51
There was no difference in the response of the groups
on the first day of treatment. However, a significant reduction
in the total symptom score was observed during the second
week of the BDP treatment period. This effect remained
throughout the rest of the period. For the individual nasal
symptoms, a significantly lower score for the BDP period was
registered for sneezing during the first week, for nasal drain-
age during the second week, for nasal itching during the third
week, and for nasal blocking only during the fourth week of
treatment (Table 4).51
On questioning, after the BDP period, 4 patients con-
sidered themselves free of trouble, 25 had improved, 10 were
unchanged, and no one had worsened; 74% considered them-
selves free of symptoms or greatly improved. After the
placebo period, no one was free of trouble, 12 had improved,
20 were unchanged, and 7 patients had worsened; 31%
considered themselves free of symptoms or greatly improved.
Of the 39 who completed the study, 25 preferred the BDP
period, 5 preferred the placebo period, and 9 found no
difference between the periods. The authors concluded that
the results were encouraging because approximately 75% of
the patients considered themselves free of trouble or im-
proved when treated with the intranasal corticosteroid, BDP.51
TABLE 7. Microscopic Investigation Before (I) and After (II) Treatment
Patients
Variables 1 2 3 4 5 6 7 8 9 10 11 12
Squamous epithelium
I  0    0 0 0  0 0 
II  0 0   0 0   0 0 0
Goblet cells
I        0 0 0  
II 0       0    
Inflammatory cells in epithelium
I  0          
II 0 0 0  0  0     
Thickening of the basal lamina
I     0       
II            
Eosinophils
I 0  0     0   0 0
II 0 0 0 0 0  0 0    
Neutrophils
I 0 0      0   0 0
II 0 0  0   0 0    0
Plasma cells
I 0  0    0 0   0 0
II   0    0 0    0
Lymphocytes
I            
II            
WAO Journal • August 2009 Intranasal Corticosteroids for Vasomotor Rhinitis
© 2009 World Allergy Organization 173
A second Swedish study on the effects of BDP
aerosol for VMR was reported from a dose-ranging, cross-
over, double-blind, placebo-controlled trial.52 Subjects,
18–61 years (average, 36 years), with persistent nasal
symptoms were studied by skin prick testing and provo-
cation testing. No relevant allergic sensitivities were found
in the 21 subjects. Each group took a dose (given in a twice
a day regimen) in a randomized fashion of placebo and
200, 400, and 800 g of the active drug during four 2-week
periods. To avoid or reduce the effects of BDP lingering on
from previous periods of treatment, the statistical evalua-
tion of the symptoms was limited to the last week of each
period.52
Although no differences in efficacy were determined
between the 3 BDP doses, all doses of BDP aerosol were
significantly more effective than placebo in reducing nasal
blockage, nasal secretions, and sneezing (P  0.05, Fig.
3).52 During the week before treatment with placebo and
BDP, the patients used altogether 80 antihistamine tablets.
During the week of treatment with placebo, the number
dropped to 20 tablets; and during the weeks with 200, 400,
and 800 g BDP, 13, 8, and 9 tablets were taken, respec-
tively. Evaluations of nasal secretions revealed that 18 of
21 patients had more than 10% eosinophils in the week
before treatment. During the periods of treatment, the
percentage of eosinophils was reduced to 10% with pla-
cebo, and to 8, 5, and 8% during treatment with 200, 400,
and 800 g BDP, respectively. The authors recommended
that the lowest effective dose of BDP be prescribed.52
Similar results were reported for a once versus twice daily
BDP dose study for the treatment of VMR.53
Budesonide
Budesonide aerosol was investigated to determine its
effect on the symptoms of patients with perennial nonallergic
rhinitis.54 Participants in the study were 22 patients aged
20–68 years (average, 42 years). All the patients had nega-
tive prick test reactions to standard allergens. Analysis of
serum IgE levels showed 9 patients 20 kU/l and 20–100
kU/l in 13 patients. The trial had a double-blind, cross-over
design randomizing the twice a day dosing of placebo 50,
200, and 800 g of budesonide with each preparation taken
for 2 weeks.54
Budesonide was significantly more effective than pla-
cebo with regard to the symptoms of nasal obstruction, nasal
drainage, and sneezing (P  0.05). No significant differences
were established between the budesonide dosages (Fig. 4).54
Objective parameters were also evaluated. Nasal airway
resistance was determined by means of anterior rhinomanom-
etry. There were no differences in respect to nasal patency
between the sitting and recumbent positions, between the pla-
cebo and budesonide groups and between the dosages within
FIGURE 6. Comparison of the efficacy of budesonide and BDP aerosols in doses of 400 g/d in a long-term study of 24 pa-
tients with perennial nonallergic rhinitis. Nasal symptom scores more than 12 months (mean  SEM).56
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budesonide (Table 5).54 Nasal eosinophilia (10% of leuko-
cytes) was present among 10 of 22 patients in the run-in period.
Eosinophilia in nasal smears was reduced by budesonide (P 
0.01). Nasal secretion was induced by the intranasal delivery of
0.2 ml metacholine bromide solution in each nostril using a De
Vilbiss #15 spray. A total of 0.4 ml containing 12 mg metacho-
line was given. Secretions were then collected for 15 minutes
through a funnel held under the subject’s nose. The metacholine
induced nasal secretion was significantly lowered by all the
treatments as compared with the amount induced during the
run-in period. Budesonide, in dosages of 200 and 800 g daily
significantly reduced the metacholine-induced secretion as com-
pared with the placebo treatment (Table 6).54
Budesonide aerosol, 2 puffs twice a day, was also studied
in 12 subjects with an age range of 22–53 years (mean age, 37
years) in a long-term open uncontrolled trial of patients with
vasomotor rhinitis. All subjects were skin test negative.55 Clin-
ical evaluations were performed after 1, 2, 4, 6, 9, and 12
months. All patients completed the 1-year trial period. A nasal
biopsy was obtained before beginning medication and after 1
year of treatment.
Symptom scores were substantially decreased by the 1
month appointment and this improvement persisted for the
whole year (Fig. 5).55 No increase in the daily dose was noted;
in fact, 3 patients, on their own, halved their daily intranasal
steroid dose from 400 to 200 g without any recurrence of
symptoms. The decrease of symptoms compared with the entry
values was statistically significant (P  0.01). The differences
between the baseline and the end of treatment biopsies were in
most cases nonexistent or very small (Table 7).55 In only 3 cases
did any of the 8 variables change by more than one degree. The
authors conclude that VMR, a “pathologic puzzle,” can be
successfully treated with INS.55
The efficacy of budesonide and BDP aerosols in
doses of 400 g/d were compared in a long-term study of
24 patients with perennial nonallergic rhinitis.56 The total
nasal symptom score showed a statistically significant
decrease from baseline at all visits in both groups, but at 6
and 12 months the reduction was significantly greater (P 
0.05) in the budesonide treatment group (Fig. 6).56
The Agency for Healthcare Research and Quality
reviewed one double-blind, placebo-controlled study with
2 doses of budesonide for nonallergic rhinitis. They found
it showed significant improvement in nasal obstruction.57
FP
FP nasal spray has been shown to have a beneficial
effect on inflammatory cells and cytokine profile. Application
of this product resulted in decreases in the number of CD3
cells, the amount of major basic protein, and the number of
tryptase-positive cells in subjects with nonallergic rhinitis.58
In addition, the use of this agent effectively lowered messen-
ger RNA expression for IL-4 and IL-5.58
FIGURE 7. Comparison of different treatment regimens of FP aqueous nasal spray (FPANS) 200 g (once daily for 8 weeks,
twice daily for 8 weeks, once daily for 4 weeks followed by twice daily for 4 weeks) in patients with nonallergic noninfectious
rhinitis. Sums of the scores of blockage, sneezing, and rhinorrhea (mean  SD).3
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In a study of 65 patients with nonallergic noninfectious
rhinitis, comparing 8 weeks of placebo with FP aqueous nasal
spray 200 g once daily, FP 200 g twice daily, and FP once
daily for 4 weeks followed by FP twice daily for 4 weeks, no
significant changes were seen for the mean sums of the scores
of blockage, sneezing, and rhinorrhea (Fig. 7).3 No significant
difference between the 4 groups was found in the before
treatment biopsies. A significant dose dependent decrease in
the immunocompetent cells was found after treatment. In the
epithelium, a marked decrease in the number of Langerhans
cells and T cells was seen. In the lamina propria, at the end of
treatment, the mast cells and eosinophils (rarely found) were
reduced if present at baseline. The authors concluded that FP
did not provide symptom improvement and the significant
dose-dependent steroid effect on immunocompetent cells
does not seem to be a clinically relevant benefit.3
A placebo controlled trial with FP, studied 35 patients
with hypertrophic inferior turbinates and a diagnosis of VMR
based on nasal symptoms, negative skin prick allergy tests,
and negative nasal cytologic examination for eosinophils.59
The dosage was administered as 1 spray/nostril twice a day,
giving a daily dose of 200 g of FP.
Treatment with FP provided significantly greater relief
from the symptom of nasal obstruction compared with pla-
cebo over the entire 3 month treatment period (P  0.001).
The FP nasal spray regimen produced statistically significant
reductions in the mucosal area of the lower turbinates (P 
0.002) and in the thickness of the nasal mucosa (P  0.001)
after 3 months compared with placebo treatment as assessed
by means of computed tomographic (CT) scanning (Fig. 8).59
However, no significant group differences were seen for the
middle turbinate mucosa, or the thickness of the maxillary
sinus or the ethmoid infindibulum mucosae.
FP nasal spray in an AM/PM divided dose of 200 and
400 g was compared with placebo in a large trial of 983
patients with perennial nonallergic rhinitis as documented
FIGURE 8. Method for measuring area
of turbinate mucosa and thickness of na-
sal, maxillary sinus, and ethmoidal infind-
ibulum mucosa.59
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by history and negative skin tests to all allergens relevant
to the region.60 Cytologic examination showed that 31%
of the subjects had prominent nasal eosinophilia (NARES
syndrome) and 69% did not have nasal eosinophilia
(non-NARES, or vasomotor). Both FP study groups dem-
onstrated significantly greater reduction in their total nasal
symptom score (TNSS) compared with placebo over the 28
day treatment period (P  0.01). The mean changes for all
patients treated with FP 200 and FP 400 was 84 and
85, respectively (maximum visual analogue score of
300). For placebo, the mean change in TNSS was 64.
There were no statistical differences between the 2 FP
treatment groups at any time point (Fig. 9).60 In the
NARES subgroup, mean changes in TNSS for the FP 200
g and placebo groups were similar to changes seen in the
total population (86 and 66 respectively); mean change
in the TNSS for the FP 400 g group was somewhat
greater (97) than change seen in the total population. In
the non NARES subgroup, mean changes in TNSS for each
treatment group were similar to changes seen in the total
population (83 and 80 in the FP 200 g and FP 400 g
groups, respectively, as opposed to 63 in the placebo
group) (Fig. 9).60 The authors concluded that FP is an
effective treatment for perennial nonallergic rhinitis with
or without eosinophilia.
Mometasone Furoate
The benefit of INS in perennial nonallergic rhinitis has
been inconsistent. A study of mometasone furoate nasal spray
(MFNS) 200 g once daily showed improvement rates to be
numerically better (56% vs. 49%) but not statistically signif-
icantly more effective than placebo (P  0.25) in reducing
overall rhinitis symptoms in a cohort of 329 subjects with
nonallergic rhinitis during a 6 week treatment period.61 How-
ever, during the follow-up period with no treatment the
relapse rates (increase in any score 1) in the subset of
improved patients were significantly higher in the MFNS
groups for both subject’s [P  0.11 (intention-to-treat), P 
0.04 (per protocol)] and investigator’s [P  0.03 (intention-
to-treat), P  0.01 (per protocol)] overall evaluations.61
BDP (400 g/d) and the intranasal anticholinergic
agent, ipratropium bromide (160 g/d) aerosol preparations
were compared in a cross-over trial in 24 patients (ages
20–77 years) with nonallergic rhinitis (negative skin prick
tests for allergic reactivity) with excessive nasal secretions.62
Significant differences between the treatments were not found
FIGURE 9. Placebo-controlled comparison of FP nasal spray given as a AM/PM divided dose of 200 and 400 g. Patient-rated
mean total nasal symptom scores (TNSS) in total, non-NARES, and NARES populations.60
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in the number of paper tissues used nor in the scorings of
nasal secretions, sneezes, and amount of nasal blockage
(Table 8).62 Nasal secretions tended to be more reduced by
ipratropium and nasal blockage and sneezing reduced more
by beclomethasone. Eight patients had eosinophilia in the
nasal smear. Three of them preferred ipratropium and 5
beclomethasone. In the 16 patients without nasal eosino-
philia, 11 preferred ipratropium and 4 beclomethasone. Of the
24 patients, 14 preferred ipratropium, 9 preferred BDP, and 1
subject had no preference (not statistically significant). The
authors concluded that it was not possible to characterize
patients who would necessarily benefit with either ipratro-
pium or BDP.62
Administration of INS therapy in combination with
other agents has been suggested for treatment of nonallergic
rhinitis. Suggestions include a topical steroid plus a topical
antihistamine63 and topical steroid plus topical ipratropium
bromide.64
CONCLUSIONS
INSs have numerous pharmacologic properties. These
include the ability to reduce inflammatory cells, cytokines,
and mediators, and their consequent effects on blood vessel,
glands, and nerves. As the pathophysiology of VMR is not
fully understood, there is the possibility that INSs could offer
therapeutic benefits. Studies to date, whereas not always simi-
larly designed and not always consistent in results, generally
suggest that treatment of this condition with INSs has value.
Further well planned clinical trials of these agents for
VMR are warranted. Endpoints that have been used in past
studies and should be considered in the future include:
Y Quantifying symptom scores—total and individual com-
ponents
Y Quantifying the perception of degree of overall im-
provement
Y Quantifying use of rescue medicine
Y Assessing relapse rates after treatment cessation
Y Assessing impact on quality of life
Y Counting number of required paper tissues
Y Measuring metacholine-induced nasal secretions
Y Measuring nasal resistance/airway patency
Y Distinguishing responses in patients with low, normal,
and high serum IgE levels
Y Distinguishing responses in patients with non-NARES
and NARES cytologic patterns
Y Evaluating biopsy patterns pre- and posttreatment
Y Assessing CT scans of inferior turbinates and nasal
mucosae
Y Assessing differences between agents in class
Y Assessing any significant dose effect
Y Correlating subjective and objective findings
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